interesting set of articles in CNN today on: "Why do drugs cost so much?"
money.cnn.comindex.htmOpen ↗ (full text below)
money.cnn.comindex.htmOpen ↗ (detailed info on: "seven
pressing questions about the fortune we spend on prescription drugs"😉
money.cnn.comindex.htmOpen ↗ (Brits and Canadians should find
this interesting. 🙂)
money.cnn.comindex.htmOpen ↗ (Healthcare myth: We spend too much)
(Brits/Canadians/Germans should find this interesting. 🙂)
money.cnn.comindex.htmOpen ↗ (Healthcare myth: More equals better)
money.cnn.comindex.htmOpen ↗ (Healthcare myth: We're in this
together) <"Not everyone really wants lower healthcare costs. Lots of people benefit when you pay
more.">...
(which is another way of saying that coz we no longer pay out of pocket (in the USA), that there
is no longer any real restraint in USA health care costs, which is likely the main reason why USA
health care costs will continue to skyrocket in the foreseeable future)
best, bill
=============
=============
Why do drugs cost so much? money.cnn.comindex.htmOpen ↗
<" The answers to seven pressing questions about the fortune we spend on prescription drugs. October
13, 2003: 11:32 AM EDT By Lisa Gibbs, Money Magazine
NEW YORK (Money Magazne) - Why do drugs cost so much?
Drug companies say that their prices reflect the enormous cost of the research and testing
required to develop new medications.
Last year, for example, they spent $32 billion on R&D -- an amount equal to about 70 percent of
the industry's profits. Moreover, most R&D money is spent on drugs that never reach the market.
The industry points out that for every 5,000 treatments tested, only five make it to clinical
trials and only one ends up in drugstores. Last year, a mere 15 drugs won FDA approval.
As a result, in recent years drugmakers have come to rely heavily on just a handful of blockbuster
drugs -- $1 billion-plus sellers. For example, 85 percent of Pfizer's $32.4 billion in sales last
year came from its 10 best-selling drugs.
Once a drug is approved, the company has a limited time before the patent expires and others can
copy the drug and compete on price, which inevitably decimates sales. Prozac sales slid 22 percent
the year its patent expired, 63 percent the year after that. Although patents last 2 0 years, the
clock starts running when the drug is first developed, not when it's approved, so the average
sales period is just 11 years.
You might ask, why don't drug companies charge even more?
Because they aren't immune to market pressures. Insurers must first agree to cover the drug, and
then they and other bulk purchasers negotiate discounts (only those without insurance pay full
freight). And pricing depends in part on how many patients are likely to use the drug, how serious
the condition it treats is (we'll pay more to tackle a life-threatening disease like cancer) and
what else is available.
When a drug enters a crowded market, the company may discount to gain a foothold. AstraZeneca, for
example, will likely price its new cholesterol-lowering drug an average of 12 percent below
Pfizer's Lipitor, says health-care fund manager Tom Wald. On the other hand, if a drug is shown to
be more effective and has fewer side effects than what's out there, insurers will pay a premium.
The other side of the pill
For consumer advocates, another set of numbers tell the story. Drugmakers' net profit margins
averaged 19 percent last year vs. 7.5 percent for all the companies in the S&P 500. The seven
largest U.S. drugmakers made $31.2 billion last year.
Simply put, critics say, the industry is greedy: They run billions of dollars' worth of ads a year
to drum up demand, employ overly aggressive tactics to extend the life of their patents and
exaggerate the cost of drug development by ignoring huge federal tax breaks for R&D and
contributions from federally funded research.
Who's right? Your answer really comes down to philosophy."